Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas
BackgroundPreviously, we reported that bevacizumab (Bev) produces histological and neuroradiographic alterations including changes in tumor oxygenation, induction of an immunosupportive tumor microenvironment, and inhibition of stemness. To confirm how those effects vary during Bev therapy, paired s...
Main Authors: | Jun Takei, Nei Fukasawa, Toshihide Tanaka, Yohei Yamamoto, Ryota Tamura, Hikaru Sasaki, Yasuharu Akasaki, Yuko Kamata, Mutsunori Murahashi, Masayuki Shimoda, Yuichi Murayama |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.898614/full |
Similar Items
-
Bevacizumab for Glioblastoma—A Promising Drug or Not?
by: Ryo Nishikawa, et al.
Published: (2013-11-01) -
CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
by: Masahiro Nishikawa, et al.
Published: (2021-03-01) -
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
by: N. García-Romero, et al.
Published: (2020-06-01) -
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
by: Moire Cuncannon, et al.
Published: (2019-05-01) -
Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
by: George Ansstas, et al.
Published: (2016-01-01)